Event schedules / NPACE 2026 December Virtual Conference: The Final Countdown - Primary Care Updates & AI for APPs

Partner CE Session: PCEC: Optimizing T2D Outcomes with GLP-1 Centered Treatment

Tuesday, December 8, 2026, – (America/New_York)
Partner CE Program

Click for Pre-Survey

Click for Post-Survey

Participants in this presentation  should be able to…

Incorporate  cardio-kidney-metabolic risk reduction principles into T2D management by   identifying patients who may benefit from GLP-1 RA-based therapy beyond   glycemic control.

Differentiate  current and emerging GLP-1 RA-based therapies by mechanism of action, route   of administration, dosing/titration considerations, glycemic and   extra-glycemic effects, and safety/tolerability profile to inform   personalized treatment selection.

Implement  practical strategies to initiate, titrate, and sustain GLP-1 RA-based   treatment in primary care, including proactive adverse effect management,   patient counseling, shared decision-making, and navigation of access barriers.

Speakers